BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amaryl (glimepiride) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Amaryl (glimepiride)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07589387-281@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Amaryl (glimepiride): Phase na readout est. (NCT07589387)
DESCRIPTION:Amaryl (glimepiride)\, phase na.\nStudy: Hypertension Treatment
  in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3\nEst
 imated primary completion: 30 April 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/glimepiride#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07589387
URL:https://assetmemo.bio/drug/glimepiride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288749-281@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Amaryl (glimepiride): Phase 3 readout est. (NCT07288749)
DESCRIPTION:Amaryl (glimepiride)\, phase 3\, Type 2 Diabetes.\nStudy: Effic
 acy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus an
 d Chronic Heart Failure With Reduced Ejection Fraction.\nEstimated primary
  completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/glimepiride#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07288749
URL:https://assetmemo.bio/drug/glimepiride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
